Spots Global Cancer Trial Database for ovarian mucinous cystadenocarcinoma
Every month we try and update this database with for ovarian mucinous cystadenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01074411 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate... | Bortezomib Carboplatin Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | NCT00002819 | Ovarian Cancer | carboplatin cyclophosphamid... mitoxantrone hy... paclitaxel autologous bone... peripheral bloo... | - 65 Years | GOG Foundation | |
| Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer | NCT00002568 | Ovarian Cancer | cisplatin paclitaxel conventional su... | - | GOG Foundation | |
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | NCT01492920 | Fatigue Malignant Ovari... Neuropathy Neurotoxicity S... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Pain Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Acetyl-L-Carnit... Placebo Questionnaire A... Quality-of-Life... | 18 Years - | GOG Foundation | |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | NCT01294293 | Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... | TLR8 Agonist VT... Diagnostic Labo... Pharmacological... Pegylated Lipos... Paclitaxel | 18 Years - | GOG Foundation | |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00217529 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pegfilgrastim carboplatin docetaxel erlotinib hydro... | 18 Years - | Fred Hutchinson Cancer Center | |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01074411 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate... | Bortezomib Carboplatin Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02101775 | Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT02111941 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Undifferentiate... Undifferentiate... | Laboratory Biom... Multi-epitope F... | 18 Years - | Mayo Clinic | |
| Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | NCT00003322 | Ovarian Cancer Primary Periton... | cisplatin paclitaxel quality-of-life... | - | GOG Foundation | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005026 | Ovarian Cancer Primary Periton... | carboplatin paclitaxel topotecan hydro... | - | GOG Foundation | |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | NCT00003644 | Ovarian Cancer | carboplatin paclitaxel | - 120 Years | GOG Foundation | |
| Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | NCT00003880 | Ovarian Cancer Primary Periton... | recombinant ade... carboplatin paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission | NCT00002977 | Ovarian Cancer | filgrastim melphalan thiotepa peripheral bloo... | 18 Years - 60 Years | Fred Hutchinson Cancer Center | |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | NCT00003644 | Ovarian Cancer | carboplatin paclitaxel | - 120 Years | GOG Foundation | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics | |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | NCT00008138 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel debulking surge... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | NCT02142803 | Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | NCT00466960 | Brenner Tumor Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Peritoneal Cavi... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | sargramostim paclitaxel albu... laboratory biom... immunologic tec... | 18 Years - | University of Washington | |
| Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00003380 | Fallopian Tube ... Ovarian Cancer Primary Periton... | etoposide pegylated lipos... | - | GOG Foundation | |
| Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00408590 | Ovarian Cancer Primary Periton... | carcinoembryoni... oncolytic measl... reverse transcr... laboratory biom... | 18 Years - 120 Years | Mayo Clinic | |
| Immunotoxin Therapy in Treating Patients With Advanced Cancer | NCT00006981 | Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton... | SS1(dsFv)-PE38 ... | 18 Years - | National Cancer Institute (NCI) | |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | NCT00060359 | Fallopian Tube ... Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Primary Periton... Stage III Ovari... Stage IV Ovaria... Undifferentiate... | Carboplatin Paclitaxel Poli... Pharmacological... | 18 Years - | GOG Foundation | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | NCT00354601 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | capecitabine docetaxel | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | NCT00008138 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel debulking surge... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | NCT00354601 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | capecitabine docetaxel | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00003944 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim carboplatin cyclophosphamid... paclitaxel topotecan hydro... peripheral bloo... | 18 Years - | Fox Chase Cancer Center | |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00331422 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel cytoreductive s... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | NCT00005026 | Ovarian Cancer Primary Periton... | carboplatin paclitaxel topotecan hydro... | - | GOG Foundation | |
| Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | NCT00002913 | Brenner Tumor Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Stage III Ovari... Stage IV Ovaria... | paclitaxel cisplatin topotecan hydro... filgrastim | - | National Cancer Institute (NCI) | |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | NCT02142803 | Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00003944 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim carboplatin cyclophosphamid... paclitaxel topotecan hydro... peripheral bloo... | 18 Years - | Fox Chase Cancer Center | |
| Immunotoxin Therapy in Treating Patients With Advanced Cancer | NCT00006981 | Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton... | SS1(dsFv)-PE38 ... | 18 Years - | National Cancer Institute (NCI) | |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer | NCT00357448 | Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Peritoneal Cavi... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | denileukin dift... intraperitoneal... laboratory biom... enzyme-linked i... flow cytometry | 18 Years - | University of Washington | |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00006235 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin pegylated lipos... | - | GOG Foundation | |
| Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | NCT00003322 | Ovarian Cancer Primary Periton... | cisplatin paclitaxel quality-of-life... | - | GOG Foundation | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | NCT00003880 | Ovarian Cancer Primary Periton... | recombinant ade... carboplatin paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | NCT00408590 | Ovarian Cancer Primary Periton... | carcinoembryoni... oncolytic measl... reverse transcr... laboratory biom... | 18 Years - 120 Years | Mayo Clinic | |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00006235 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin pegylated lipos... | - | GOG Foundation | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | NCT00002600 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim carboplatin cyclophosphamid... autologous bone... peripheral bloo... | 18 Years - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | NCT00017303 | Ovarian Cancer Primary Periton... | carboplatin oglufanide diso... paclitaxel conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003967 | Fallopian Tube ... Ovarian Cancer Primary Periton... | etoposide topotecan hydro... | 18 Years - | GOG Foundation | |
| Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003967 | Fallopian Tube ... Ovarian Cancer Primary Periton... | etoposide topotecan hydro... | 18 Years - | GOG Foundation | |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00331422 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel cytoreductive s... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00006235 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin pegylated lipos... | - | GOG Foundation | |
| Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00897039 | Fallopian Tube ... Ovarian Cancer Primary Periton... | flow cytometry immunohistochem... | - | National Cancer Institute (NCI) | |
| Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | NCT00354601 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | capecitabine docetaxel | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | NCT00017303 | Ovarian Cancer Primary Periton... | carboplatin oglufanide diso... paclitaxel conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | NCT01081262 | Borderline Ovar... Ovarian Mucinou... Recurrent Fallo... Recurrent Ovari... Stage IA Fallop... Stage IA Ovaria... Stage IB Fallop... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIC Fall... Stage IIIC Ovar... Stage IV Fallop... Stage IV Ovaria... | Bevacizumab Capecitabine Carboplatin Laboratory Biom... Oxaliplatin Paclitaxel Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00939809 | Fallopian Tube ... Malignant Ovari... Ovarian Brenner... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Primary Periton... Recurrent Ovari... Undifferentiate... | Urokinase-Deriv... Laboratory Biom... | 18 Years - | GOG Foundation | |
| Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer | NCT00652691 | Ovarian Cancer Peritoneal Cavi... | filgrastim carboplatin cyclophosphamid... topotecan hydro... autologous hema... peripheral bloo... | 18 Years - 70 Years | Mayo Clinic | |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02101775 | Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT00483782 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bevacizumab carboplatin paclitaxel questionnaire a... study of socioe... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | NCT01080521 | Cognitive Side ... Malignant Ovari... Ovarian Brenner... Ovarian Carcino... Ovarian Chorioc... Ovarian Clear C... Ovarian Dysgerm... Ovarian Embryon... Ovarian Endomet... Ovarian Mixed G... Ovarian Mucinou... Ovarian Polyemb... Ovarian Sarcoma Ovarian Seromuc... Ovarian Serous ... Ovarian Teratom... Ovarian Yolk Sa... Stage I Ovarian... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Ovaria... Stage IV Primar... Undifferentiate... | Cognitive Asses... Quality-of-Life... | 18 Years - | GOG Foundation | |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | NCT00003644 | Ovarian Cancer | carboplatin paclitaxel | - 120 Years | GOG Foundation | |
| TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00022347 | Fallopian Tube ... Ovarian Cancer Primary Periton... | canfosfamide hy... | 18 Years - | National Cancer Institute (NCI) | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | NCT00008138 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin paclitaxel debulking surge... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003967 | Fallopian Tube ... Ovarian Cancer Primary Periton... | etoposide topotecan hydro... | 18 Years - | GOG Foundation | |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT00217529 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | pegfilgrastim carboplatin docetaxel erlotinib hydro... | 18 Years - | Fred Hutchinson Cancer Center | |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00079430 | Brenner Tumor Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Primary Periton... Stage II Ovaria... Stage III Ovari... Stage IV Ovaria... | adjuvant therap... paclitaxel carboplatin bevacizumab | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | NCT01081262 | Borderline Ovar... Ovarian Mucinou... Recurrent Fallo... Recurrent Ovari... Stage IA Fallop... Stage IA Ovaria... Stage IB Fallop... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIC Fall... Stage IIIC Ovar... Stage IV Fallop... Stage IV Ovaria... | Bevacizumab Capecitabine Carboplatin Laboratory Biom... Oxaliplatin Paclitaxel Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00003380 | Fallopian Tube ... Ovarian Cancer Primary Periton... | etoposide pegylated lipos... | - | GOG Foundation | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
